Skip to main content

Table 2 Mutational status and local recurrence

From: Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery

 

Local recurrence

Patients

No

Yes

N=90

N=8

N=98

KRAS Mutation

  No

67

(74.4%)

8

(100.0%)

75

(76.5%)

  yes

23

(25.6%)

0

(0.0%)

23

(23.5%)

BRAF Mutation

  No

89

(98.9%)

7

(87.5%)

96

(98.0%)

  yes

1

(1.1%)

1

(12.5%)

2

(2.0%)

PIK3CA Mutation

  No

86

(95.6%)

8

(100.0%)

94

(95.9%)

  yes

4

(4.4%)

0

(0.0%)

4

(4.1%)

All mutations

At least one mutation

  No

65

(72.2%)

7

(87.5%)

72

(73.5%)

  yes

25

(27.8%)

1

(12.5%)

26

(26.5%)

Nb of mutations

  0

65

(72.2%)

7

(87.5%)

72

(73.5%)

  1

22

(24.4%)

1

(12.5%)

23

(23.5%)

  2

3

(3.3%)

0

(0.0%)

3

(3.1%)